Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors, in combination with letrozole or fulvestrant, have been approved for treating hormone receptor-positive breast cancer. Even though the therapy shows benefits in some patients, resistance develops in other treated patients.
Cancer both imitates and hijacks the nervous system, to the extent that some researchers consider tumor-neuronal interactions a new hallmark of cancer. Unsurprisingly, the parallels are particularly strong in brain cancers. Glioblastomas form electrically interconnected networks, similar to neuronal-glial gap junctions, that help them grow. Now, researchers have identified key players in these networks, as well as ways to target them and possibly take down the networks.
A new acute coronary syndrome detection system developed by Neuome Peptides Pte. Ltd.’s aims to make tests for the frequently lethal condition faster, more precise and less invasive. Neuome’s Truheart is a point-of-care assay for cardiovascular disease that is used in the company’s established Instadetect assay development platform. The assay measures the biomarkers troponins I and T and myoglobin.
Prenetics Global Ltd. agreed to acquire a majority stake in Act Genomics Holdings Co. Ltd. as part of a move to target the precision oncology market. Prenetics will issue 19.9 million class A ordinary shares and pay $20 million in cash to complete the acquisition.
Two deals for antibody-drug conjugates inked since May between Merck & Co. Inc. and Sichuan Kelun-Biotech Pharmaceutical Co. Ltd. have blossomed eight months later into the year’s biggest agreement, one that could bring Kelun-Biotech up to $9.3 billion in development, regulatory and sales milestones.
Astex Therapeutics Ltd. and Taiho Pharmaceutical Co. Ltd. have divulged GTPase KRAS (G12C mutant), (G12D mutant) and/or (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
RSS
